Literature DB >> 9043936

In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients.

D M See1, N Broumand, L Sahl, J G Tilles.   

Abstract

Extracts of Echinacea purpurea and Panax ginseng were evaluated for their capacity to stimulate cellular immune function by peripheral blood mononuclear cells (PBMC) from normal individuals and patients with either the chronic fatigue syndrome or the acquired immunodeficiency syndrome. PBMC isolated on a Ficoll-hypaque density gradient were tested in the presence or absence of varying concentrations of each extract for natural killer (NK) cell activity versus K562 cells and antibody-dependent cellular cytotoxicity (ADCC) against human herpesvirus 6 infected H9 cells. Both echinacea and ginseng, at concentrations > or = 0.1 or 10 micrograms/kg, respectively, significantly enhanced NK-function of all groups. Similarly, the addition of either herb significantly increased ADCC of PBMC from all subject groups. Thus, extracts of Echinacea purpurea and Panax ginseng enhance cellular immune function of PBMC both from normal individuals and patients with depressed cellular immunity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9043936     DOI: 10.1016/s0162-3109(96)00125-7

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  38 in total

1.  Ineffectiveness of echinacea for prevention of experimental rhinovirus colds.

Authors:  R B Turner; D K Riker; J D Gangemi
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Korean red ginseng slows depletion of CD4 T cells in human immunodeficiency virus type 1-infected patients.

Authors:  Heungsup Sung; Sang-Moo Kang; Moo-Song Lee; Tai Gyu Kim; Young-Keol Cho
Journal:  Clin Diagn Lab Immunol       Date:  2005-04

3.  Structural characterization and immunological activities of the water-soluble oligosaccharides isolated from the Panax ginseng roots.

Authors:  Debin Wan; Lili Jiao; Hongmei Yang; Shuying Liu
Journal:  Planta       Date:  2011-12-20       Impact factor: 4.116

4.  Neuroprotective effects of a new skin care formulation following ultraviolet exposure.

Authors:  B L Fonseca; B C dos Santos; P Martins; C Bonorino; T W F Corte; V D da Silva; M E Bauer
Journal:  Cell Prolif       Date:  2011-12-13       Impact factor: 6.831

5.  Mast cell degranulation and calcium influx are inhibited by an Echinacea purpurea extract and the alkylamide dodeca-2E,4E-dienoic acid isobutylamide.

Authors:  Travis V Gulledge; Nicholas M Collette; Emily Mackey; Stephanie E Johnstone; Yasamin Moazami; Daniel A Todd; Adam J Moeser; Joshua G Pierce; Nadja B Cech; Scott M Laster
Journal:  J Ethnopharmacol       Date:  2017-10-14       Impact factor: 4.360

6.  The in vitro immunomodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with chronic fatigue syndrome.

Authors:  D M See; P Cimoch; S Chou; J Chang; J Tilles
Journal:  Integr Physiol Behav Sci       Date:  1998 Jul-Sep

7.  Effects of ginseng treatment on neutrophil chemiluminescence and immunoglobulin G subclasses in a rat model of chronic Pseudomonas aeruginosa pneumonia.

Authors:  Z Song; A Kharazmi; H Wu; V Faber; C Moser; H K Krogh; J Rygaard; N Hoiby
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

8.  Dietary supplementation with Echinacea and development of immunity to challenge infection with coccidia.

Authors:  Patricia C Allen
Journal:  Parasitol Res       Date:  2003-07-29       Impact factor: 2.289

9.  Enhancement of innate and adaptive immune functions by multiple Echinacea species.

Authors:  Zili Zhai; Yi Liu; Lankun Wu; David S Senchina; Eve S Wurtele; Patricia A Murphy; Marian L Kohut; Joan E Cunnick
Journal:  J Med Food       Date:  2007-09       Impact factor: 2.786

10.  Traditional chinese medicine for chronic fatigue syndrome.

Authors:  Rui Chen; Junji Moriya; Jun-Ichi Yamakawa; Takashi Takahashi; Tsugiyasu Kanda
Journal:  Evid Based Complement Alternat Med       Date:  2008-02-27       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.